Table 2.
Baseline Characteristics of Study Participants by MLL status Classification
| Characteristics | Total | MLL status | P value | |
|---|---|---|---|---|
| Negative(n = 93) | Positive(n = 31) | |||
| Gender, n(%) | 0.291 | |||
| Male | 74 (59.7%) | 53 (57.0%) | 21 (67.7%) | |
| Female | 50 (40.3%) | 40 (43.0%) | 10 (32.3%) | |
| Age (y), median(range) | 3.9 (0.4–14.9) | 4.5 (1.4–14.9) | 3.1 (0.4–12.5) | 0.019 |
| Age group(y) | 0.002 | |||
| < 1 | 4 (3.2%) | 0 (0.0%) | 4 (12.9%) | |
| ≥ 1, < 10 | 103 (83.1%) | 80 (86.0%) | 23 (74.2%) | |
| ≥ 10 | 17 (13.7%) | 13 (14.0%) | 4 (12.9%) | |
| Chemotherapy protocol, n(%) | 0.706 | |||
| SCCLG-ALL-2016 Protocol | 27 (21.8%) | 21 (22.6%) | 6 (19.4%) | |
| GD-ALL-2008 Protocol | 97 (78.2%) | 72 (77.4%) | 25 (80.6%) | |
| Initial WBC (×109/L),median(range) | 8.9 (0.2–895.5) | 6.5 (0.2–354.4) | 22.6 (3.5–895.5) | < 0.001 |
| WBC group, n(%) | < 0.001 | |||
| < 50 × 109/L | 101 (81.5%) | 83 (89.2%) | 18 (58.1%) | |
| ≥ 50 × 109/L | 23 (18.5%) | 10 (10.8%) | 13 (41.9%) | |
| Initial Hb (g/L),median(range) | 80.5 (50.0–149.0) | 80.0 (50.0–139.0) | 82.0 (50.0–149.0) | 0.762 |
| Hb group | 0.333 | |||
| < 110 g/L | 103 (83.1%) | 79 (84.9%) | 24 (77.4%) | |
| ≥ 110 g/L | 21 (16.9%) | 14 (15.1%) | 7 (22.6%) | |
| Initial PLT (×109/L), median(range) | 64.5 (6.0–499.0) | 70.0 (6.0–499.0) | 57.0 (9.0–416.0) | 0.619 |
| PLT group | 0.273 | |||
| < 100 × 109/L | 82 (66.1%) | 59 (63.4%) | 23 (74.2%) | |
| ≥ 100,×109/L | 42 (33.9%) | 34 (36.6%) | 8 (25.8%) | |
| Risk group, n(%) | < 0.001 | |||
| SR | 29 (23.4%) | 27 (29.0%) | 2 (6.5%) | |
| IR | 53 (42.7%) | 44 (47.3%) | 9 (29.0%) | |
| HR | 42 (33.9%) | 22 (23.7%) | 20 (64.5%) | |
| Immunophenotype, n(%) | < 0.001 | |||
| Pro-B | 7(5.6%) | 2(2.2%) | 5(16.1%) | |
| Common-B | 75(60.5%) | 67(72.0%) | 8(25.8%) | |
| T | 13(10.5%) | 6(6.5%) | 7(22.6%) | |
| Pre-B | 7(5.6%) | 4(4.3%) | 3(9.7%) | |
| Immature-B | 22(17.8%) | 14(15.1%) | 8(25.8%) | |
| Prednisone Response, n(%) | 0.377 | |||
| PGR | 106 (85.5%) | 81 (87.1%) | 25 (80.6%) | |
| P PR | 18 (14.5%) | 12 (12.9%) | 6 (19.4%) | |
| D15 BM, n(%) | 0.036 | |||
| M1 | 100 (80.6%) | 79 (84.9%) | 21 (67.7%) | |
| M2/M3 | 24 (19.4%) | 14 (15.1%) | 10 (32.3%) | |
| D33 BM, n(%) | 0.736 | |||
| M1 | 121 (97.6%) | 91 (97.8%) | 30 (96.8%) | |
| M2/M3 | 3 (2.4%) | 2 (2.2%) | 1 (3.2%) | |
| D15 MRD, n(%) | 0.294 | |||
| < 0.1% | 45 (40.9%) | 40 (43.0%) | 5 (29.4%) | |
| ≥ 0.1% | 65 (59.1%) | 53 (57.0%) | 12 (70.6%) | |
| D33 MRD, n(%) | 0.046 | |||
| < 0.01% | 98 (87.5%) | 84 (90.3%) | 14 (73.7%) | |
| ≥ 0.01% | 14 (12.5%) | 9 (9.7%) | 5 (26.3%) | |
| SCT, n(%) | 0.147 | |||
| No | 118 (95.2%) | 90 (96.8%) | 28 (90.3%) | |
| Yes | 6 (4.8%) | 3 (3.2%) | 3 (9.7%) | |
Abbreviation: WBC white blood cell, Hb haemoglobin, PLT platelet, CNS L central nervous system leukemia, SR standard risk, IR intermediate risk, HR high risk, PGR prednisone good response, PPR prednisone poor response, MRD minimal residual disease evaluation, BM bone marrow, SCT stem cell transplantation